ApoA-1水平与老年急性心肌梗死患者心梗后院内心衰的相关性

目的:探讨老年急性心肌梗死患者住院期间血清载脂蛋白A-1(ApoA-1)水平与早发心梗后心衰的关系。方法:回顾性收集我院2020-01—2021-04诊断为急性心肌梗死的老年患者207例,根据患者是否发生心衰将其分为心衰组(n=93)和非心衰组(n=114),比较两组患者临床基线资料(年龄、性别、既往病史等)及生化指标(血脂、肾功能)的差异。采用Logistic回归分析ApoA-1与老年急性心梗后心衰的相关性。运用ROC曲线评价ApoA-1和其它相关指标对老年患者早发心梗后心衰的预测效能。结果:与非心衰组患者比较,心衰组患者总胆固醇、高密度脂蛋白胆固醇以及ApoA-1水平均降低(P<0.05);多因素Logistic回归分析结果显示ApoA-1和NT-proBNP与老年患者早发心梗后心衰的发生独立相关(P<0.05);ROC曲线分析结果表明ApoA-1和NT-proBNP预测老年患者早发心梗后心衰事件的AUC分别为0.624(95%CI:0.547-0.702,P<0.01)和0.749(95%CI:0.680-0.819,P<0.01),当二者联合应用后其预测...     

慢性阻塞性肺疾病合并2型糖尿病的老年患者肺功能、免疫失衡研究

目的 探讨慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)合并2型糖尿病(type 2 diabetes mellitus,T2DM)老年患者的肺功能、免疫水平变化及其临床意义.方法 选取北京市垂杨柳医院2015年1月至2016年1月收治的120例COPD患者进行研究,其中合并T2DM患者48例(T2DM组)、单纯COPD患者62例(单纯COPD组),比较两组患者肺功能、免疫指标的差异.结果 T2DM组的CD3+、CD4+、CD4+/CD8+测定值均低于单纯COPD组患者(t=4.209、t=4.598、t=5.617,P<0.05),T2DM组CD8+测定值高于单纯COPD组(t=4.157,P<0.05);T2DM组的血清IFN-γ、IL-10的水平均显著的低于单纯COPD组患者(t=4.839、t=8.529,P<0.05),T2DM组的血清IL-4、IL-8的水平高于单纯COPD组(t=4.209、t=4.517,P<0.05);T2DM组的用力肺活量(forced vital capatiry,FVC)、用力呼气容积(forced expiratory volume in 1 second,FEV lung for carbon monoxide,DLCO)水平均显著的低于单纯COPD组患者(t=3.006、t=5.966,t=6.210,P<0.05).结论 老年COPD合并T2DM患者的肺功能损害更加严重,可能与炎症反应水平增强及免疫失衡有关.     

血清CA125与慢性心力衰竭严重程度及近期预后相关性分析

目的 探究血清CA125对慢性心力衰竭严重程度及与近期预后相关性.方法 通过对我院2012年3月至2015年5月心血管内科就诊收治的72例慢性心力衰竭患者做回顾性分析,并根据心功能分级分为慢性心衰Ⅰ~Ⅱ级组,慢性心衰Ⅲ组,慢性心衰Ⅳ组(各24例),比较各组患者CA125、NT-proBNP表达水平及LVEF指数,并分析其与近期预后相关性.结果 CHF各组CA125、NT-proBNP的表达水平均明显高于健康组,LVEF水平低于健康组(P<0.05),且慢性心衰Ⅲ、Ⅳ级组CA125、NT-proBNP的表达水平明显高于慢性心衰Ⅰ~Ⅱ级组,LVEF水平低于慢性心衰Ⅰ~Ⅱ级组(P<0.05),慢性心衰Ⅳ级组CA125、NT-proBNP的表达水平明显高于慢性心衰Ⅲ组,且LVEF水平低于慢性心衰Ⅲ组(P<0.05);CHF组患者血清CA125水平与NT-proBNP呈正相关(rs=0.548,P=0.012),与LVEF呈负相关(rs=-0.515,P=0.021);单因素分析:CA125、NT-proBNP、LVEF指标水平在终点事件发生组和未发生组间存在差异(P<0.05);多因素分析:高血清CA125、高血清NT-proBNP、低LVEF水平是影响终点事件发生的独立危险因素.结论 CA125在CHF患者中存在高表达,随着CHF病变严重程度增加而升高,和NT-proBNP指标呈正相关关系,和LVEF指标呈负相关关系,且血清高浓度CA125是影响终点事件发生的危险独立因素,故其可能作为临床CHF患者近期预后情况的评判指标.     

芪苈强心胶囊对慢性心力衰竭患者氨基末端脑钠肽前体的影响

目的:观察芪苈强心胶囊对慢性心力衰竭(CHF)患者血浆氨基末端脑钠肽前体(NT-proBNP)水平的影响。方法:CHF患者114例,随机分为治疗组(n=58)和对照组(n=56),所有患者根据心衰治疗指南给予常规抗心衰治疗,治疗组在此基础上给予芪苈强心胶囊治疗3个月。采用电化学发光免疫分析技术检测治疗前后CHF患者NT-proBNP水平,并评价心功能疗效。结果:治疗3个月后,两组患者NT-proBNP水平均较治疗前显著下降(P<0.05),且治疗组较对照组下降幅度更显著(P<0.05)。治疗组心功能总有效率明显高于对照组(P<0.05)。结论:芪苈强心胶囊治疗CHF患者,可显著降低其NT-proBNP水平,心功能疗效也优于常规治疗。     

探讨仫佬族慢性心力衰竭与N末端B型钠尿肽前体的关系

目的 探讨仫佬族慢性心力衰竭(CHF)与N末端B型钠尿肽前体(NT-proBNP)的关系;方法 选仫佬族慢性心力衰竭和汉族慢性心力衰竭患者各30例为观察组,同期仫佬族健康体检者20例为对照组.采用热景UPT-3A上转发光免疫分析法检测各组血浆NT-proBNP水平.对比各组血浆NT-proBNP水平的差异,分析仫佬族CHF患者与血浆NT-proBNP水平的相关性;结果 观察组血浆NT-proBNP水平明显高于对照组(P＜0.05),而仫佬族组和汉族组血浆NT-proBNP水平无明显差异(P＞0.05),心功能分级Ⅱ、Ⅲ、Ⅳ级患者血浆NT-proBNP水平呈逐渐增高趋势(P＜0.05),并与心功能分级呈正相关(r =0.912,P=0.006);结论 仫佬族CHF与血浆NT-proBNP水平密切相关,并与心功能分级呈正相关.故仫佬族地区亦可将血浆NT-proBNP水平作为慢性心力衰竭的一项常规监测指标.     

COPD患者血清胱抑素C、NT-proBNP、尿酸水平与病情严重程度及心脏受累的相关性分析

目的探讨慢性阻塞性肺疾病(COPD)患者血清胱抑素C(CysC)、氨基末端脑钠肽前体(NT-proBNP)、尿酸(UA)、C反应蛋白(CRP)水平与病情严重程度及心脏受累的相关性。方法检测112例COPD患者的血清CysC、NT-proBNP、UA、CRP水平,治疗3个月后复查。测定并计算COPD患者的FEV1占预计值百分比(FEV1%预计值),分析CysC、NT-proBNP、UA、CRP与FEV1%预计值的相关性,用受试者工作曲线(ROC)分析CysC、NT-proBNP、UA、CRP对慢性肺源性心脏病(CCP)的诊断效能,计算曲线下面积(AUC)。结果COPD急性期患者血清CysC、NT-proBNP、UA、CRP水平高于COPD稳定期患者(P﹤0.05);Ⅳ级患者血清CysC水平高于Ⅰ、Ⅱ、Ⅲ级患者(P﹤0.05),血清NT-proBNP、UA水平比较,Ⅲ级﹥Ⅱ级﹥Ⅰ级(P﹤0.05),血清CRP比较,Ⅳ级﹥Ⅲ级﹥Ⅱ级﹥Ⅰ级(P﹤0.05);血清CysC、NT-proBNP、UA、CRP水平与FEV1%预计值呈显著负相关(P﹤0.05);合并CCP组患者血清CysC、NT-proBNP、UA、CRP水平高于无CCP组患者(P﹤0.05);血清CysC、NT-proBNP、UA、CRP诊断CCP的AUC值分别为0.602、0.932、0.770、0.682;COPD患者治疗3个月后血清CysC、NT-proBNP、UA、CRP水平均明显下降(P﹤0.05)。结论COPD患者血清CysC、NT-proBNP、UA、CRP水平与病情严重程度成显著正相关,对合并CCP也有较高的诊断价值,为COPD患者病情评估提供了重要的血清学依据。     

外周血中性粒细胞/淋巴细胞比值在慢性阻塞性肺病相关肺动脉高压患者中的预后价值

目的：探讨外周血中性粒细胞/淋巴细胞比值(neutrophil/lymphocyte ratio,NLR)对慢性阻塞性肺病(chronic obstructive pulmonary disease,COPD)相关肺动脉高压患者预后的评判价值。方法：选择2013年1月至2014年3月收治入上海交通大学医学院附属新华医院急诊科的200例COPD相关肺动脉高压(pulmonary hypertension,PH)患者为研究对象,对其进行至少2年的生存随访,随访终点为全因死亡,按照生存情况分为生存组和死亡组;记录各组入院24 h的一般临床资料,血常规[C反应蛋白(C-reactive protein,CRP)、中性粒细胞计数(neutrophils count,NEU)及淋巴细胞计数(lymphocyte count,LYM)并计算两者间比值(NLR)]、肌酐、尿素氮、胆红素、WHO肺动脉高压功能分级、肺动脉收缩压等;绘制受试者工作特征(receiver operating characteristic,ROC)曲线,分析NLR预测患者预后的临床价值;并以Kaplan-Meier法绘制观察指标不同水平下的生存曲线,进行生存分析。COX回归分析各指标提示预后的价值。结果：死亡组患者NLR,CRP,WHO肺动脉高压功能分级、肺动脉收缩压、尿素氮、肌酐、中性粒细胞计数高于生存组,淋巴细胞计数低于生存组,差异均具有统计学意义(P<0.05)。根据ROC曲线分析,NLR的ROC曲线下面积(AUC)为0.720(P<0.01),高于肌酐(AUC=0.716)、中性粒细胞计数(AUC=0.655)、肺动脉收缩压(AUC=0.652)及CRP(AUC=0.643)。当NLR截断值为4.7时,其灵敏度为74.2%,特异度为72.0%。Kaplan-Meier生存曲线分析显示,NLR值水平较高组预后明显差于水平较低组(P<0.01)。单因素Cox回归分析提示NLR是提示患者不良预后的危险因素,多因素Cox回归分析(P>0.05)。结论：NLR水平与COPD相关肺动脉高压患者临床预后呈明显相关;NLR水平越高则提示病情较重,预后较差。     

N端脑钠肽诊断伴肾功能不全心衰的准确性评价

目的:评价N端脑钠肽(NT-proBNP)诊断伴肾功能不全心衰的准确性。方法:选取50～70岁伴肾功能不全心衰患者104例,测定体重、体表面积和血肌酐(Crea)浓度,计算肌酐清除率(eGFR),并分为三组:eGFR在60～90ml/min为实验I组,eGFR在30～60ml/min为实验II组,eGFR<30ml/min为实验III组,分别测定各组血浆NT-proBNP水平。对照组为50～70岁无心衰、肾功能正常人50例。应用ROC软件计算曲线下面积,评价应用NT-proBNP诊断伴不同程度肾功能不全心衰的准确性。结果:实验I组的NT-proBNP明显高于对照组(P<0.05),实验II组和实验III组的NT-proBNP、Crea、eGFR均明显高于对照组(P<0.05);三组血浆NT-proBNP水平与eGFR密切相关,相关系数为-0.534(P<0.01);三组病例所得到的ROC曲线下面积分别为0.988、0.948、0.908。结论:eGFR影响NT-proBNP诊断伴肾功能不全心衰的准确性;应根据eGFR分层界定NT-proBNP临界值,以提高NT-proBNP诊断伴肾功能不全心衰的准确性。     

脑电双频指数联合血浆中枢神经特异性蛋白和D-二聚体对颅脑损伤患者预后的评估

目的 探究脑电双频指数(BIS)联合血浆中枢神经特异性蛋白(S100 β)、D-二聚体(DD)对颅脑损伤患者预后的评估价值。方法 回顾性分析厦门市第五医院在2019年5月至2022年5月期间收治的125例颅脑损伤患者资料,根据28 d病死情况分为存活组和死亡组,比较两组患者一般资料、入院24 h内平均BIS、血浆S100 β、DD水平,利用logistic回归分析、受试者工作特征(ROC)曲线探究颅脑损伤患者预后影响因素及预测效能。结果 28 d病死率为30.4%(38/125例)。死亡组年龄大于存活组,急性生理与慢性健康评分表Ⅱ(APACHE Ⅱ)、S100 β、DD水平高于存活组,格拉斯哥昏迷评分(GCS)、平均BIS值低于存活组(P均<0.05)。logistic回归分析显示APACHE Ⅱ、GCS、入院24 h内平均BIS值、血浆S100 β、DD是颅脑损伤患者死亡的独立影响因素(P<0.05);ROC曲线显示入院24 h内平均BIS值、血浆S100 β、DD预测颅脑损伤患者预后的曲线下面积(AUC)分别为0.897、0.816、0.820,BIS分别联合S100 ...     

血清BNP、CA125表达在老年慢性心力衰竭预后评估中的应用

目的检测老年慢性心力衰竭患者血清B型钠尿肽(BNP)、CA125水平,分析其与患者生存预后的关系。方法选取2013年1月至2015年1月我院收治的115例老年慢性心力衰竭(CHF)患者为研究对象,同期30例体检健康者为对照组。检测两组受试者血清BNP及CA125水平,分析两者与心功能分级的相关性;分析影响患者预后的因素,并采用受试者工作特征曲线(ROC)分析患者生存预后的效能。结果对照组血清BNP、CA125明显低于CHF组患者(P<0.05),Ⅳ级BNP水平明显高于Ⅲ级及Ⅱ级患者(q=44. 237、38.232,均P <0. 05),Ⅳ级CA125水平明显高于Ⅲ级及Ⅱ级患者(q=36.329、25.425,均P<0.05);Spearman相关性分析显示,BNP及CA125均与CHF患者心功能分级呈正相关(r_s=7. 803、5. 331,均P<0.05);单因素分析显示死亡组患者既往存在高血压史、冠心病史、伴有肾损伤、心功能分级Ⅲ～Ⅳ级分布比例明显高于生存组,差异有统计学意义(P<0.05),死亡组患者血清BNP、CA125水平明显高于生存组,血清高密度脂蛋白胆固醇(HDL-C)水平明显低于生存组,比较差异均有统计学意义(P<0.05)。进一步回归分析显示,心功能Ⅲ～Ⅳ级、血清高BNP及CA125为患者死亡的独立影响因素(P<0.05);心功能分级、血清BNP及CA125均对患者生存预后具有一定的诊断价值,联合检测诊断CHF预后的效能明显高于任一单一指标诊断。结论血清BNP、CA125在CHF患者体内水平较高,联合检测可提高诊断患者预后的效能。     

COPD患者血清ANP、BNP和CNP测定及其临床意义

目的：探讨慢性阻塞性肺疾病（COPD）患者血清心钠素（ANP）、脑钠肽（BNP）、C型钠尿肽（CNP）水平的变化及其临床意义。方法：采用放射免疫分析79例COPD患者和36例健康对照组血清ANP、BNP和CNP水平,并进行统计分析。结果：COPD组血清ANP、BNP和CNP水平显著地高于健康对照组（t=3.6841,P〈0.01;t=11.70,P〈0.01;t=2.177,P〈0.05）,但Ⅰ、Ⅱ、Ⅲ和Ⅳ级组间血清ANP、BNP和CNP水平方差检验无显著性意义（F=2.123、F=1.515、F=0.165,P均〉0.05）。相互间相关性分析揭示：ANP、BNP和CNP三者间均呈显著正相关（r=0.369,P〈0.01;r=0.354,P〈0.01;r=0.426,P〈0.01）。住院期间死亡的患者血清ANP、BNP和CNP水平显著地高于好转出院的患者（t=5.149,P〈0.01;t=4.875,P〈0.01;t=2.830,P〈0.01）。结论：COPD患者血清ANP、BNP和CNP显著升高,且与病人的稳定情况、肺动脉压力及预后相关。     

Pulmonary gas exchange during hemodialysis: a comparison of subjects with and without COPD on bicarbonate hemodialysis

Little is known about the effect of hemodialysis (HD) on gas exchange in subjects with chronic obstructive pulmonary disease (COPD). The purpose of this study was to examine blood gases and pH in COPD patients undergoing HD with bicarbonate dialysate. We studied thirteen subjects with COPD and thirteen controls (CON). All were dialyzed for 4 hrs against a bicarbonate HD solution. Blood gases, pH and HCO(3) (-) were initially analyzed (t(0)) and, during HD, at 30 min (t(0.5)), 1 hr (t(1)) and 4 hrs (t(4)). At t(0), a statistically significant difference was observed for PO(2) (CON: 84.7±3.60, COPD: 72.19±4.92; p<0.001). For the first hr, PO(2) decreased, and at t(1), oxygen was required for 6 COPD subjects. By t(4), there was no significant difference in PO(2) between groups. The alveolar-arterial gradient (ΔA-a) remained different between groups (P<0.001, all times), with increasing ΔA-a for both groups up to t(1) and decreasing over the remaining 3 hr. For both groups, at t(4), ΔA-a was higher than at t(0) (p<0.001). For PCO(2), both groups demonstrated increases from t(0) to t(1) (p=0.0004), with COPD having PCO(2) higher than CON at t(0.5) and t(1) (p<0.05 for both); by t(4), PCO(2) levels decreased to nearly the same as at t(0). Over the 4 hr treatment, HCO(3) (-) and pH increased significantly for both groups; however no significant difference was observed between COPD and CON. Markedly increased ΔA-a is observed during HD in some COPD patients. COPD patients retain more CO(2). However, the effect of HCO(3) (-) leads to mild metabolic alkalosis at t(4).     

血浆脑钠肽检测在慢性阻塞性肺疾病患者低氧血症中的意义

探讨血浆B型钠尿肽（BNP）和N末端B型钠尿肽原（NT-proBNP）检测在慢性阻塞性肺疾病（COPD）患者低氧血症中的临床意义。测定85例COPD急性发作期患者血浆BNP、NT-proBNP水平及动脉血氧分压（PaO2）。结果显示,COPD患者伴不同程度低氧血症,血浆BNP和NT-proBNP均明显高于正常对照组（P〈0.05）,且重度低氧血症组患者血浆BNP和NT-proBNP浓度均明显高于中度低氧血症组和轻度低氧血症组,差异有统计学意义（P〈0.05）;患者组PaO2水平与相对应的BNP和NT-proBNP水平间呈负相关（分别为r=-0.703、P〈0.05和r=-0.782、P〈0.05）;血浆BNP和NT-proBNP检测的阳性率分别为42.4%和52.9%,差异有统计学意义（P〈0.05）。结论：COPD患者低氧血症可导致血浆BNP和NT-proBNP浓度增高,且与PaO2水平呈负相关,常规检测血浆BNP和NT-proBNP浓度对及时了解COPD患者早期心功能损害情况、改善疗效有重要意义。     

血液流变学用于估测慢性阻塞性肺疾病肺动脉高压的可行性

通过对８９例慢性阻塞性肺疾病（ＣＯＰＤ）患者肺动脉顺应性（Ｃｐａ）、肺动脉平均压（ＰＡＭＰ）测定和血液流变学的同步研究，获得三个回归方程式，①ＰＡＭＰ＝０．４２５＋０．３５２·ηｂ（Ｈ）；②ＰＡＭＰ＝１．８５７＋０．０７３·ηｂ（Ｌ）；③ＰＡＭＰ＝０．３４９＋０．４５·ＩＲ，并扩大验证４８例。提示肺动脉压力、肺动脉顺应性与血液粘度、红细胞刚性指数有一定的相关性，且能估算群体ＰＡＭＰ，但对个体不能精确计算。     

SOX5基因多态性与慢性阻塞性肺疾病及并发症肺动脉高压的关联性分析

目的:通过观察慢性阻塞性肺疾病(COPD)稳定期患者、COPD合并肺动脉高压(PH)患者及健康者之间SOX5基因单核苷酸多态性(SNPs)的分布差异,初步探索SOX5基因多态性与COPD相关PH易感性的关联。方法:连续选择2013年4月~2015年4月就诊于宁夏人民医院总院及宁南分院呼吸内科的COPD稳定期患者250例,根据COPD诊治指南(2013年版)诊断标准入组,并且就诊当天全部进行超声心动图检查,根据肺动脉收缩压(PASP)结果分为COPD合并PH组(PASP≥50 mm Hg)103例和COPD非PH组(PASP50 mm Hg)147例。健康对照组选择同期在宁夏人民医院体检的健康者127例。使用Sequenom Mass ARRAY SNP检测系统检测所有受试者SOX5基因rs10842262和rs11046966位点的基因型,统计基因型频率并对比各组间差异。结果:健康对照组与COPD组之间(包括COPD合并PH及未合并PH组的全部患者)以及COPD合并PH组与COPD非PH组之间在年龄、性别和吸烟指数上的差别均无统计学显著性。健康对照组与COPD组之间SOX5基因rs10842262位点及rs11046966位点基因型频率分布的差异均存在统计学显著性(P0.05)。COPD合并PH组与COPD非PH组之间SOX5基因rs10842262位点及rs11046966位点各基因型频率分布的差异无统计学显著性。结论:SOX5基因rs10842262和rs11046966位点的基因多态性与COPD的易感性相关,但与COPD相关PH的易感性还不能认为有关联。     

Diagnostic accuracy of sputum outcomes in chronic stable asthma

BACKGROUND: Asthma with non-remitting airflow obstruction may not always be differentiated from COPD with airway hyperreactivity. Many attempts have been made to find useful markers for the distinction between these two disorders. OBJECTIVE AND METHODS: In order to help the finding of a useful marker for the diagnosis of asthma in the population of patients with airway obstruction we analysed the diagnostic accuracy of sputum eosinophils and sputum ECP in 91 patients with asthma, 15 patients with chronic bronchitis, 32 patients with chronic obstructive pulmonary disease (COPD) and 20 controls subjects, by performing ROC analysis. RESULTS: Sputum eosinophils were above the normal range of our laboratory (0-3.7%) in 48 asthma patients and in six COPD patients, while sputum ECP (normal range < 85 microg/L) was high in 65 asthma patients, in 24 COPD patients and in nine chronic bronchitis patients. The ROC analysis revealed that sputum eosinophils count (AUC = 0.82) was more accurate than both sputum ECP levels (AUC = 0.56) (P < 0.0001) and beta2-reversibility (AUC = 0.53) (P = 0.0001) in differentiating asthmatic from non-asthmatic subjects (COPD, chronic bronchitis patients and normal subjects). The diagnostic accuracy of ECP was similar to that of bronchial reversibility (P = 0.76). When ROC analysis was performed by including only patients with airway obstruction (36 asthmatics with airway obstruction and COPD patients), both eosinophil count (AUC = 0.77) and beta2-reversibility (AUC = 0.66) were more accurate than ECP measurement (AUC = 0.39) in discriminating asthmatics from COPD patients (P < 0.00001 and P = 0.04, respectively). CONCLUSION: Sputum eosinophils seem to be valid markers for detecting asthma in a population of patients with airway obstruction. Moreover, the higher diagnostic accuracy of eosinophils in the sputum compared to sputum ECP and bronchial reversibility reinforces the role of cytological analysis of sputum in the diagnosis of chronic stable bronchial asthma.     

Frequency of Pulmonary Hypertension in Patients with COPD due to Biomass Smoke and Tobacco Smoke

Objectives; Pulmonary hypertension (PH) is a common and well established complication of chronic obstructive pulmonary disease (COPD). Its presence is associated with decreased survival. This study was designed to investigate the PH frequency and its relations in hospitalized tobacco and biomass related COPD patients. Methods and Results; The study was a retrospective review of inpatients with COPD defined as a history of tobacco or biomass smoking, Pulmonary function tests (PFT) within stable status, an echocardiogram within stable status. PH was defined as systolic pulmonary artery pressure (sPAP) >35 mmHg. Of the 694 individuals, 600 had suitable aspects for inclusion of study. All Females were biomass exposer and males were tobacco smoker. The Prevalence of PH was found more frequent in females than males. It was more prominent in moderate level COPD cases (56,2% and 37,5%, P<0,002). Both groups had airflow limitation, hypercapnia and hypoxemia, but no differences were found in terms of PaCO(2) and PaO2. However, FEV1 % was lower in males than females (p<0,005). On the other hand, FVC % was lower in the females compared with the males (p < 0.02). When analyzing the influence of PFT and demographic parameters on PH in separate COPD level groups, the results a bit varied among the groups. Conclusion; Our study demonstrated that PH frequency is higher in female COPD cases due to biomass smoke than in male COPD cases due to tobacco smoke. The influence of FVC % on the risk of a person having PH increased with increasing COPD level.     

Systematic Review and Meta-Analysis of Pulmonary Hypertension Specific Therapy for Exercise Capacity in Chronic Obstructive Pulmonary Disease

Some patients with chronic obstructive pulmonary disease (COPD) have pulmonary hypertension (PH) that adversely affects survival. We performed a systematic review and meta-analysis to assess whether PH-specific therapies have an effect for stable COPD. Data sources were Medline, EMBASE, Cochrane Central Register of Controlled Trials, Korea med and references from relevant publications. Randomized prospective trials that compared PH specific therapy in COPD for more than 6 weeks with placebo were included. The outcomes were the exercise capacity and adverse events. Four randomized controlled trials involving 109 subjects were included in the analysis. Two trials involved bosentan, one sildenafil and one beraprost. The studies varied in duration of treatment from 3 to 18 months. In a pooled analysis of four trials, exercise-capacity was not significantly improved with PH-specific treatment for COPD (risk ratio, -5.1; 95% CI, -13.0 to 2.8). COPD with overt PH significantly improved the exercise capacity (mean difference, 111.6; 95% CI, 63.3 to 159.9) but COPD with PH unknown did not (mean difference, 26.6; 95% CI, -24.3 to 77.5). There was no significant difference in hypoxemia (mean difference, 2.6; 95% CI, -3.7 to 8.8). PH specific treatments have a significant effect in improving exercise capacity in COPD with overt PH.